WO2025161898 - ANTI-OX40 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/161898
Publication Date
07.08.2025
International Application No.
PCT/CN2025/071507
International Filing Date
09.01.2025
Title **
[English]
ANTI-OX40 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-OX40 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
AN, Wenqian
WANG, Zilin
LIU, Baihong
LIU, Qiang
ZHU, Tao
Priority Data
PCT/CN2024/075517
02.02.2024
CN
PCT/CN2024/092997
14.05.2024
CN
PCT/CN2024/110179
06.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3535 | |
| EPO | Filing, Examination, Granting | 38112 | |
| Japan | Filing, Examination, Granting | 3390 | |
| South Korea | Filing, Examination, Granting | 4862 | |
| USA | Filing, Examination, Granting | 18190 |
Total:
68,089
Contact Us
Abstract[English]
Provided are anti-OX40 antibodies or antigen binding fragments, and antigen-binding protein constructs (e.g. bispecific antibodies or antigen-binding fragments thereof), wherein the antigen-binding protein constructs specifically bind to two distinct antigenic epitopes on OX40.[French]
L'invention concerne des anticorps anti-OX40 ou des fragments de liaison à l'antigène, et des constructions de protéine de liaison à l'antigène (par exemple des anticorps bispécifiques ou des fragments de liaison à l'antigène de ceux-ci), les constructions de protéine de liaison à l'antigène se liant de manière spécifique à deux épitopes antigéniques distincts sur OX40.